Health

Bharat Biotech to upgrade Covaxin facilities


The WHO said in a statement late Saturday that the suspension of Covaxin was in response to the results of the post-EUL (emergency use authorization) test, held between 14 and 22 March, and the need to undertake process and facility upgrades to address GMP (good manufacturing practice) deficiencies was recently identified.

The World Health Organization (WHO) today confirmed the discontinuation of supply of Covaxin produced by Bharat (Biotech) through United Nations purchasing agencies and recommended The country that has received the vaccine should take appropriate action.

Bharat Biotech on Sunday said it had nothing else to add to an earlier statement, where it said it was working on further improvements and upgrades to ensure that Covaxin production continues to meet regulatory requirements are increasing globally.

“During the recent WHO post-EUL audit, Bharat Biotech agreed with the WHO team on the scope of the planned improvement activities and indicated that they would be implemented as soon as practical,” it said. in a statement on April 1.

Hyderabad-based vaccine maker Bharat Biotech later announced to temporarily suspend production of its Covid-19 vaccine on its manufacturing facilities.

“Bharat Biotech has announced that it is temporarily suspending Covaxin production on its production facilities, after fulfilling its supply obligations with purchasing authorities and seeing a decrease in demand,” it said.

The company will focus on pending facility maintenance, process and facility optimization activities for the coming period, the company said.

Source: IANS



Source link

news7h

News7h: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, Sports...at the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button
Immediate Peak